2019
Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment.
Huntington SF. Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment. Hematology 2019, 2019: 252-259. PMID: 31808838, PMCID: PMC6913455, DOI: 10.1182/hematology.2019000030.Peer-Reviewed Original ResearchConceptsFirst-line treatmentClassic Hodgkin lymphomaBrentuximab vedotinNovel therapiesLarge-scale clinical trialsLarge randomized trialsHodgkin lymphoma treatmentRisk of progressionStandard cytotoxic therapiesChemotherapy cyclesDurable remissionsMultiagent chemotherapyMost patientsClinical outcomesRandomized trialsMedical oncologyCytotoxic therapyHodgkin's lymphomaLymphoma treatmentClinical trialsSelect populationIncomplete responseAlkylator chemotherapyChemotherapyAdvanced stage
2018
Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma
Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA. Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. Journal Of Clinical Oncology 2018, 36: jco.18.00122. PMID: 30285558, PMCID: PMC6241679, DOI: 10.1200/jco.18.00122.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioFirst-line settingFirst-line therapyBrentuximab vedotinHodgkin's lymphomaHealth care costsStage IIICare costsDirect health care costsLifetime health care costsOpen-label trialCohort of patientsRisk of progressionUS payer perspectiveMarkov decision-analytic modelCost-effectiveness ratioDecision analytic modelFavourable cost effectivenessCost-effectiveness analysisStandard ABVDClinical outcomesPayer perspectiveParametric survival distributionsIndication-specific pricingCost effectiveness